X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (61042) 61042
Magazine Article (46) 46
Transcript (20) 20
Newsletter (19) 19
Publication (17) 17
Newspaper Article (14) 14
Book / eBook (8) 8
Book Chapter (5) 5
Book Review (5) 5
Dissertation (4) 4
Reference (2) 2
Report (2) 2
Conference Proceeding (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (59543) 59543
female (42318) 42318
antineoplastic combined chemotherapy protocols - therapeutic use (38217) 38217
male (35040) 35040
middle aged (34975) 34975
oncology (33655) 33655
antineoplastic combined chemotherapy protocols - adverse effects (31179) 31179
aged (29811) 29811
adult (28921) 28921
chemotherapy (22428) 22428
treatment outcome (17703) 17703
cancer (17234) 17234
antineoplastic combined chemotherapy protocols - administration & dosage (10234) 10234
aged, 80 and over (8801) 8801
combined modality therapy (8624) 8624
hematology (8467) 8467
care and treatment (8333) 8333
cisplatin - administration & dosage (8251) 8251
disease-free survival (8198) 8198
neoplasm staging (8181) 8181
therapy (7854) 7854
drug administration schedule (7424) 7424
adolescent (7122) 7122
prognosis (7033) 7033
fluorouracil - administration & dosage (6926) 6926
survival rate (6752) 6752
breast neoplasms - drug therapy (6723) 6723
medicine & public health (6643) 6643
antineoplastic agents - therapeutic use (6533) 6533
retrospective studies (6513) 6513
cisplatin (6270) 6270
survival (6146) 6146
survival analysis (6101) 6101
antineoplastic agents - adverse effects (5628) 5628
follow-up studies (5581) 5581
lung neoplasms - drug therapy (5518) 5518
cyclophosphamide - administration & dosage (5434) 5434
research (5351) 5351
doxorubicin - administration & dosage (5181) 5181
trial (5169) 5169
pharmacology & pharmacy (5125) 5125
child (4671) 4671
radiotherapy (4656) 4656
dose-response relationship, drug (4559) 4559
hematology, oncology and palliative medicine (4502) 4502
cisplatin - adverse effects (4363) 4363
analysis (4276) 4276
deoxycytidine - analogs & derivatives (4252) 4252
antineoplastic agents (4237) 4237
breast cancer (4168) 4168
clinical trials (4131) 4131
carcinoma (4114) 4114
antineoplastic agents - administration & dosage (4078) 4078
prospective studies (4067) 4067
drug therapy (4018) 4018
risk factors (4013) 4013
animals (3978) 3978
remission induction (3970) 3970
chemotherapy, adjuvant (3955) 3955
metastasis (3876) 3876
antimitotic agents (3875) 3875
neoplasms - drug therapy (3860) 3860
surgery (3839) 3839
young adult (3829) 3829
toxicity (3815) 3815
health aspects (3777) 3777
fluorouracil - adverse effects (3730) 3730
combination (3653) 3653
paclitaxel - administration & dosage (3653) 3653
tumors (3640) 3640
time factors (3618) 3618
neoplasm metastasis (3616) 3616
deoxycytidine - administration & dosage (3603) 3603
paclitaxel (3506) 3506
carcinoma, non-small-cell lung - drug therapy (3500) 3500
etoposide - administration & dosage (3414) 3414
child, preschool (3412) 3412
vincristine - administration & dosage (3375) 3375
fluorouracil (3366) 3366
carboplatin - administration & dosage (3224) 3224
breast neoplasms - pathology (3222) 3222
patients (3128) 3128
cyclophosphamide (3124) 3124
kaplan-meier estimate (3100) 3100
cyclophosphamide - adverse effects (3086) 3086
doxorubicin - adverse effects (3030) 3030
colorectal neoplasms - drug therapy (2988) 2988
adenocarcinoma - drug therapy (2979) 2979
docetaxel (2924) 2924
disease progression (2919) 2919
cancer therapies (2874) 2874
phase-ii (2810) 2810
doxorubicin (2804) 2804
clinical trials as topic (2711) 2711
carboplatin (2682) 2682
gemcitabine (2679) 2679
recurrence (2671) 2671
cancer research (2634) 2634
neutropenia - chemically induced (2631) 2631
5-fluorouracil (2608) 2608
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (57266) 57266
Japanese (1783) 1783
German (825) 825
Chinese (585) 585
French (578) 578
Russian (297) 297
Spanish (243) 243
Italian (130) 130
Polish (121) 121
Hungarian (82) 82
Dutch (43) 43
Czech (24) 24
Portuguese (20) 20
Danish (15) 15
Hebrew (11) 11
Norwegian (11) 11
Serbian (11) 11
Romanian (10) 10
Korean (9) 9
Ukrainian (9) 9
Bulgarian (7) 7
Swedish (6) 6
Croatian (5) 5
Finnish (4) 4
Slovak (4) 4
Bosnian (3) 3
Turkish (3) 3
Arabic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA : the journal of the American Medical Association, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | FIRE-3 | THERAPY | FOLFIRI PLUS CETUXIMAB | PHASE-II | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | TUMORS | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Randomization | Oxaliplatin | Monoclonal antibodies | Tumors
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 379, Issue 9828, pp. 1791 - 1799
Summary Background The intensity of chemotherapy and need for additional radiotherapy in patients with advanced stage Hodgkin's lymphoma has been unclear... 
Internal Medicine | Radiotherapy Dosage | Doxorubicin/adverse effects | Etoposide/adverse effects | Procarbazine/adverse effects | Prospective Studies | Hodgkin Disease/drug therapy | Humans | Middle Aged | Proportional Hazards Models | Male | Treatment Outcome | Positron-Emission Tomography | Antineoplastic Combined Chemotherapy Protocols/adverse effects | Prednisone/adverse effects | Treatment Failure | Adolescent | Survival Analysis | Adult | Female | Cyclophosphamide/adverse effects | Vincristine/adverse effects | Neoplasm Staging | Bleomycin/adverse effects | SURVIVAL | ABVD | MEDICINE, GENERAL & INTERNAL | COMBINATIONS | POSITRON-EMISSION-TOMOGRAPHY | DISEASE | PROGNOSTIC SCORE | RISK | STANFORD-V | PROGRESSION | MOPP/ABV HYBRID | Doxorubicin - therapeutic use | Hodgkin Disease - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Hodgkin Disease - drug therapy | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - therapeutic use | Bleomycin - adverse effects | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Chemotherapy | Usage | Care and treatment | PET imaging | Diagnosis | Hodgkin's disease | Cancer | Medical imaging | Meetings | Patient safety | Oncology | Lymphomas | Histology | Radiation therapy | Ovarian cancer
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 4, pp. 338 - 351
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 23, pp. 2167 - 2177
... than standard chemotherapy in patients with ALK -positive lung cancer. Rearrangements of the anaplastic lymphoma kinase ( ALK... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Crizotinib | Treatment outcome | Chemotherapy | Usage | Care and treatment | Lung cancer | Analysis | Dosage and administration | Comparative analysis | Risk factors | Cancer | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2014, Volume 32, Issue 13, pp. 1302 - 1308
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 05/2017, Volume 2017, Issue 5, pp. CD007941 - CD007941
...): chemotherapy with escalated BEACOPP (bleomycin/etoposide/doxorubicin/cyclophosphamide/vincristine/procarbazine/prednisone... 
Procarbazine | Vinblastine | Hodgkin Disease | Antineoplastic Combined Chemotherapy Protocols | Etoposide | Prednisone | Doxorubicin | Vincristine | Disease Progression | Randomized Controlled Trials as Topic | Dacarbazine | Hodgkin Lymphoma | Cyclophosphamide | Blood disorders | Bleomycin | Hodgkin’s lymphoma | Child health | Medicine General & Introductory Medical Sciences | Haematological malignancies | Cancer | EXTENDED-FIELD RADIOTHERAPY | DOSE-ESCALATION | MEDICINE, GENERAL & INTERNAL | BASE-LINE | FINAL ANALYSIS | INTENSIFIED CHEMOTHERAPY | RANDOMIZED-TRIAL | INITIAL TREATMENT | STUDY-GROUP GHSG | CURRENT CLINICAL-TRIALS | GONADAL-FUNCTION | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hodgkin Disease - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Young Adult | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - administration & dosage | Bleomycin - administration & dosage | Bleomycin - adverse effects | Procarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Vincristine - adverse effects | Doxorubicin - adverse effects | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 386, Issue 9999, pp. 1156 - 1164
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 19, pp. 1823 - 1833
Journal Article